Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis

被引:53
作者
Ioannidou, Eleni
Siempos, Ilias I.
Falagas, Matthew E.
机构
[1] Alfa Inst Biomed Sci, Athens 15123, Greece
[2] Henry Dunant Hosp, Dept Med, Athens, Greece
[3] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA
关键词
ICU-acquired pneumonia; healthcare-associated pneumonia; ventilator-associated pneumonia; respiratory tract infections;
D O I
10.1093/jac/dkm385
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Aerosolized antibiotics are a widely recognized treatment for patients with cystic fibrosis (CF). We sought to clarify their role in the treatment of non-CF patients with nosocomial pneumonia by performing a meta-analysis of randomized controlled trials (RCTs) that compared administration of antimicrobials via the respiratory tract (with or without concurrent usage of systemic antibiotics) with control treatment. Methods: An extensive search of PubMed, Scopus, Cochrane Central Register of Controlled Trials, Current Contents and bibliographies from retrieved publications was made. Results: Five RCTs were included in the meta-analysis. Administration of antimicrobials via respiratory tract (either inhaled or endotracheally instilled) as opposed to control was associated with better treatment success in intention-to-treat [fixed effect model: odds ratio (OR) = 2.39, 95% confidence interval (CI) 1.29-4.44; random effects model: OR = 2.75, 95% CI 1.06-7.17] and in clinically evaluable patients (fixed effect model: OR = 3.14, 95% CI 1.48-6.70; random effects model: OR = 3.07, 95% CI 1.15-8.19). There were no statistically significant differences between therapeutic regimens regarding all-cause mortality (fixed effect model: OR = 0.84, 95% CI 0.43-1.64; random effects model: OR = 0.71, 95% CI 0.27-1.88), microbiological success (fixed effect model: OR = 2.06, 95% CI 0.91-4.68; random effects model: OR = 2.23, 95% CI 0.64-7.71) and toxicity (fixed effect model: OR = 0.34, 95% CI 0.04-2.53; random effects model: OR = 0.36, 95% CI 0.04-3.16). Conclusions: The limited available evidence seems not to preclude a benefit from the administration of antimicrobial agents via the respiratory tract for treating nosocomial pneumonia.
引用
收藏
页码:1216 / 1226
页数:11
相关论文
共 44 条
[1]   Bronchial constriction and inhaled colistin in cystic fibrosis [J].
Alothman, GA ;
Ho, B ;
Alsaadi, MM ;
Ho, SL ;
O'Drowsky, L ;
Louca, E ;
Coates, AL .
CHEST, 2005, 127 (02) :522-529
[3]   Use of colistin in the treatment of multiple-drug-resistant gram-negative infections [J].
Berlana, D ;
Llop, JM ;
Fort, E ;
Badia, AB ;
Jódar, R .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (01) :39-47
[4]   DOUBLE-BLIND-STUDY OF ENDOTRACHEAL TOBRAMYCIN IN THE TREATMENT OF GRAM-NEGATIVE BACTERIAL PNEUMONIA [J].
BROWN, RB ;
KRUSE, JA ;
COUNTS, GW ;
RUSSELL, JA ;
CHRISTOU, NV ;
SANDS, ML .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (02) :269-272
[5]   Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients [J].
Cantón, R ;
Cobos, N ;
de Gracia, J ;
Baquero, F ;
Honorato, J ;
Gartner, S ;
Alvarez, A ;
Salcedo, A ;
Oliver, A ;
García-Quetglas, E .
CLINICAL MICROBIOLOGY AND INFECTION, 2005, 11 (09) :690-703
[6]  
Conway S P, 2005, Chron Respir Dis, V2, P35, DOI 10.1191/1479972305cd045rs
[7]  
Deem, 2007, RESP CARE, V52, P421
[8]   METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188
[9]   A history of nebulization [J].
Dessanges, JF .
JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 2001, 14 (01) :65-71
[10]   Local administration of polymyxins into the respiratory tract for the prevention and treatment of pulmonary infections in patients without cystic fibrosis [J].
Falagas, M. E. ;
Kasiakou, S. K. .
INFECTION, 2007, 35 (01) :3-10